NATICK, Mass., May 8 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its ALTRUA(TM) family of pacemakers. ALTRUA is Boston Scientific's most advanced pacemaker and delivers enhanced therapies while maintaining its small size and battery longevity. It is the first Boston Scientific-branded pacemaker to treat bradycardia, a condition in which the heart beats too slowly -- usually less than 60 beats per minute -- depriving the body of sufficient oxygen.
"FDA approval of Boston Scientific's ALTRUA family of pacemakers -- especially following the European approval of ALTRUA we announced yesterday -- further demonstrates the significant progress we have made rebuilding our CRM organization and reinvigorating our product pipeline," said Fred Colen, Executive Vice President, Operations and Technology, Cardiac Rhythm Management. "Pacemakers are the most implanted device in the cardiac rhythm management industry and we look forward to making the ALTRUA family broadly available to physicians and their patients."
The ALTRUA pacemaker provides physicians with diagnostic and
therapeutic capabilities that enable them to tailor the therapy to meet
specific patient requirements:
-- Multiple Atrial Ventricular (AV) Delay programming options: These
options are designed to reduce unnecessary right ventricular (RV)
pacing, without dropping ventricular beats, a key distinction from
other competitive RV pacing algorithms. The ALTRUA 60 series also
includes an enhanced AV search hysteresis feature, now with an
extendable AV delay out to 400 milliseconds, providing physicians with
additional flexibility to tailor device programming for unique patient
-- Stored Onset Electrograms (EGM): This feature provides diagnostic
information about the patient's heart rhythm before the onset of an
arrhythmia, enabling physicians to more easily and effectively
troubleshoot patient arrhythmias. Boston Scientific's proprietary
design enables continuous onset EGM monitoring without reducing battery
longevity, a key difference from most competitive pacemakers.
-- Minute Ventilation (MV) Blended Sensor: This proprietary technology
treats a condition called Chronotropic Incompetence (CI), which is the
inability of the heart to regulate its rate appropriately in response
to physical activity and emotional stress. Boston Scientific's MV
Blended Sensor is the only sensor that has been shown to restore
Chronotropic Competence, enabling a patient's heart rate to function
appropriately in different situations such as carrying groceries or
climbing stairs. This feature is only available in the ALTRUA 60 and
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, regulatory approval of our products, new product launches, competitive offerings, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property;
litigation; financial market conditions; and, future business decisions
made by us and our competitors. All of these factors are difficult or
impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A-
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A
- Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
thereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.
CONTACT: Paul Donovan
Boston Scientific Corporation
Boston Scientific Corporation
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved